STAT

3 challenges to watch in global health in 2020

Houston, we’ve got a polio problem, will cases of the mysterious polio-like ailment spike again, and whither dengue vaccines? Here are three challenges to watch in global health in 2020.

New Year’s Day may usher in a new decade, but our crystal ball suggests some old problems will remain key global health issues in 2020.

We’re sticking out our neck a bit and leaving the long-long-long-running Ebola outbreak in the Democratic Republic of the Congo off our list of top public health stories to watch in the coming year. Call us crazy optimists — no one ever has before! — but we’re hopeful that despite recent violence in the outbreak zone, the downward trend that has accelerated in recent months means this nightmare epidemic will finally end sometime in early-ish 2020. Warning: The final few miles of the road will likely be bumpy.

So Ebola aside, what do the tea leaves tell us about the public health stories we’ll be paying attention to in 2020? Read

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Lilly Buying A Plant, A Pfizer Antibiotic, And More
Eli Lilly agreed to acquire a manufacturing facility in Wisconsin from Nexus Pharmaceuticals to produce injectable medicines amid shortages of Mounjaro and Zepbound.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Drug Shortages, Medicare Spending On An Alzheimer’s Drug, And More
Medicare estimates a new Alzheimer’s drug could cost the program billions of dollars by next year — well beyond what Wall Street or the drug’s manufacturer project.
STAT2 min readCrime & Violence
STAT+: Pharmalittle: We’re Reading About A Medicare Price-negotiation Ruling, Pharma’s Slipping Reputation, And More
A U.S. judge dealt a blow to two drugmakers challenging the authority for Medicare to negotiate the prices of prescription drugs.

Related Books & Audiobooks